Symbols / GDTC $1.00 +1.19% CytoMed Therapeutics Limited
GDTC Chart
About
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.73M |
| Enterprise Value | 10.39M | Income | -3.98M | Sales | 1.14M |
| Book/sh | 0.43 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -6.67 | PEG | — |
| P/S | 10.25 | P/B | 2.32 | P/C | — |
| EV/EBITDA | -2.91 | EV/Sales | 9.07 | Quick Ratio | 5.17 |
| Current Ratio | 5.17 | Debt/Eq | 7.04 | LT Debt/Eq | — |
| EPS (ttm) | -0.26 | EPS next Y | -0.15 | EPS Growth | — |
| Revenue Growth | -25.20% | Earnings | — | ROA | -27.48% |
| ROE | -50.28% | ROIC | — | Gross Margin | 94.06% |
| Oper. Margin | -278.37% | Profit Margin | 0.00% | Shs Outstand | 11.73M |
| Shs Float | 3.77M | Short Float | 3.37% | Short Ratio | 4.62 |
| Short Interest | — | 52W High | 3.68 | 52W Low | 0.73 |
| Beta | — | Avg Volume | 591.02K | Volume | 5.22K |
| Target Price | — | Recom | None | Prev Close | $0.99 |
| Price | $1.00 | Change | 1.19% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.96
Latest analyst target
3. DCF / Fair value
$-4.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.96
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-10 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2024-06-11 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2023-12-04 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2023-07-21 | init | Benchmark | — → Speculative Buy | $5 |
- Rising R&D loss as CytoMed (NASDAQ: GDTC) advances γδ T cell therapies - Stock Titan ue, 31 Mar 2026 13
- GDTC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI Sun, 05 Apr 2026 08
- Why Did CytoMed Therapeutics Stock Jump 19% Today? - Stocktwits ue, 14 Oct 2025 07
- CytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia Expansion - TipRanks ue, 31 Mar 2026 21
- CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - simplywall.st Fri, 06 Feb 2026 08
- GDTC 20-F & SEC Filings - Yahoo Finance ue, 31 Mar 2026 07
- 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga Wed, 04 Feb 2026 08
- Biotech seeks investor views on share-based access to cell therapy - Stock Titan ue, 13 Jan 2026 08
- CytoMed Therapeutics Strengthens Future with Advanced Therapies - timothysykes.com hu, 05 Feb 2026 08
- symbol__ Stock Quote Price and Forecast - CNN Mon, 18 Dec 2023 16
- GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView ue, 23 Jan 2024 08
- Royal Caribbean (NYSE: RCL) launches unsecured notes sale to finance Celebrity Xcel - Stock Titan ue, 18 Nov 2025 08
- GDTC Forecast — Price Prediction for 2026. Should I Buy GDTC? - Intellectia AI Wed, 28 May 2025 08
- CytoMed Therapeutics Limited (GDTC) Stock Price, News, Quote & History - Yahoo! Finance Canada hu, 29 Jun 2023 06
- CytoMed Therapeutics (GDTC) Stock Forecast and Price Target 2026 - MarketBeat Sat, 11 May 2024 14
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.32
+366.74%
|
0.07
|
0.00
|
0.00
|
| Operating Revenue |
|
0.32
+366.74%
|
0.07
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.07
+297.13%
|
0.02
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
0.07
+297.13%
|
0.02
|
0.00
|
0.00
|
| Gross Profit |
|
0.26
+389.49%
|
0.05
|
0.00
|
0.00
|
| Operating Expense |
|
4.50
+41.32%
|
3.18
-17.17%
|
3.84
+106.99%
|
1.86
|
| Research And Development |
|
2.22
+16.13%
|
1.91
+20.12%
|
1.59
+4.40%
|
1.52
|
| Selling General And Administration |
|
1.84
+45.60%
|
1.27
-1.44%
|
1.28
+223.37%
|
0.40
|
| Selling And Marketing Expense |
|
0.05
+128.64%
|
0.02
-28.60%
|
0.03
|
0.00
|
| General And Administrative Expense |
|
1.79
+44.01%
|
1.24
-0.71%
|
1.25
+214.98%
|
0.40
|
| Salaries And Wages |
|
1.32
+112.41%
|
0.62
+36.37%
|
0.45
+115.58%
|
0.21
|
| Other Gand A |
|
0.47
-10.92%
|
0.53
+2.50%
|
0.51
+177.98%
|
0.18
|
| Other Operating Expenses |
|
0.20
+263.66%
|
-0.12
-114.34%
|
0.86
+571.33%
|
-0.18
|
| Total Expenses |
|
4.57
+42.69%
|
3.20
-16.73%
|
3.84
+106.99%
|
1.86
|
| Operating Income |
|
-4.24
-35.49%
|
-3.13
+18.54%
|
-3.84
-106.99%
|
-1.86
|
| EBITDA |
|
-3.57
-64.98%
|
-2.17
+41.46%
|
-3.70
-41.67%
|
-2.61
|
| Normalized EBITDA |
|
-3.71
-50.75%
|
-2.46
+25.48%
|
-3.31
-27.86%
|
-2.59
|
| Reconciled Depreciation |
|
0.40
+19.75%
|
0.34
-12.01%
|
0.38
-2.98%
|
0.39
|
| EBIT |
|
-3.98
-58.92%
|
-2.50
+38.71%
|
-4.08
-35.83%
|
-3.00
|
| Total Unusual Items |
|
0.14
-52.84%
|
0.30
+175.49%
|
-0.39
-1407.75%
|
-0.03
|
| Total Unusual Items Excluding Goodwill |
|
0.14
-52.84%
|
0.30
+175.49%
|
-0.39
-1407.75%
|
-0.03
|
| Special Income Charges |
|
0.29
|
0.00
|
0.00
-100.00%
|
0.00
|
| Impairment Of Capital Assets |
|
0.01
|
0.00
|
0.00
|
—
|
| Net Income |
|
-3.98
-58.16%
|
-2.52
+39.11%
|
-4.13
-31.99%
|
-3.13
|
| Pretax Income |
|
-4.00
-58.47%
|
-2.52
+38.98%
|
-4.13
-32.04%
|
-3.13
|
| Net Non Operating Interest Income Expense |
|
0.10
-65.36%
|
0.30
+26.84%
|
0.23
+290.48%
|
-0.12
|
| Interest Expense Non Operating |
|
0.02
+2.92%
|
0.02
-60.39%
|
0.05
-59.03%
|
0.13
|
| Net Interest Income |
|
0.10
-65.36%
|
0.30
+26.84%
|
0.23
+290.48%
|
-0.12
|
| Interest Expense |
|
0.02
+2.92%
|
0.02
-60.39%
|
0.05
-59.03%
|
0.13
|
| Interest Income Non Operating |
|
0.12
-61.00%
|
0.32
+11.18%
|
0.29
+13525.13%
|
0.00
|
| Interest Income |
|
0.12
-61.00%
|
0.32
+11.18%
|
0.29
+13525.13%
|
0.00
|
| Other Income Expense |
|
0.14
-54.27%
|
0.31
+159.40%
|
-0.52
+54.43%
|
-1.15
|
| Other Non Operating Income Expenses |
|
0.01
|
—
|
-0.10
+90.94%
|
-1.09
|
| Gain On Sale Of Security |
|
-0.15
-148.87%
|
0.30
+175.49%
|
-0.39
-1391.77%
|
-0.03
|
| Gain On Sale Of Business |
|
0.29
|
0.00
|
0.00
|
—
|
| Tax Provision |
|
0.00
|
0.00
-100.00%
|
0.00
-60.18%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.07
-1407.75%
|
-0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.00
-58.47%
|
-2.52
+38.98%
|
-4.13
-31.99%
|
-3.13
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.98
-58.16%
|
-2.52
+39.11%
|
-4.13
-31.99%
|
-3.13
|
| Net Income From Continuing And Discontinued Operation |
|
-3.98
-58.16%
|
-2.52
+39.11%
|
-4.13
-31.99%
|
-3.13
|
| Net Income Continuous Operations |
|
-4.00
-58.47%
|
-2.52
+38.98%
|
-4.13
-31.99%
|
-3.13
|
| Minority Interests |
|
0.02
+207.55%
|
0.01
+1784.31%
|
0.00
+12.76%
|
0.00
|
| Normalized Income |
|
-4.12
-46.43%
|
-2.81
+26.05%
|
-3.81
-22.39%
|
-3.11
|
| Net Income Common Stockholders |
|
-3.98
-58.16%
|
-2.52
+39.11%
|
-4.13
-31.99%
|
-3.13
|
| Diluted EPS |
|
—
|
—
|
-0.39
-36.26%
|
-0.29
|
| Basic EPS |
|
—
|
—
|
-0.39
-36.26%
|
-0.29
|
| Basic Average Shares |
|
—
|
—
|
10.63
-2.83%
|
10.94
|
| Diluted Average Shares |
|
—
|
—
|
10.63
-2.83%
|
10.94
|
| Diluted NI Availto Com Stockholders |
|
-3.98
-58.16%
|
-2.52
+39.11%
|
-4.13
-31.99%
|
-3.13
|
| Amortization |
|
0.03
+138.11%
|
0.01
+474.17%
|
0.00
-12.52%
|
0.00
|
| Amortization Of Intangibles Income Statement |
|
0.03
+138.11%
|
0.01
+474.17%
|
0.00
-12.52%
|
0.00
|
| Depreciation Amortization Depletion Income Statement |
|
0.23
+85.29%
|
0.12
+17.63%
|
0.10
-6.88%
|
0.11
|
| Depreciation And Amortization In Income Statement |
|
0.23
+85.29%
|
0.12
+17.63%
|
0.10
-6.88%
|
0.11
|
| Depreciation Income Statement |
|
0.20
+79.25%
|
0.11
+7.83%
|
0.10
-6.76%
|
0.11
|
| Earnings From Equity Interest |
|
-0.01
-146.43%
|
0.01
+144.12%
|
-0.03
+7.00%
|
-0.03
|
| Gain On Sale Of PPE |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Insurance And Claims |
|
0.00
-100.00%
|
0.09
-66.63%
|
0.28
|
0.00
|
| Other Taxes |
|
0.01
+12.60%
|
0.01
+26.29%
|
0.01
-5.45%
|
0.01
|
| Rent And Landing Fees |
|
0.01
+63.83%
|
0.00
+88.78%
|
0.00
-22.63%
|
0.00
|
| Rent Expense Supplemental |
|
0.01
+63.83%
|
0.00
+88.78%
|
0.00
-22.63%
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
10.07
-18.60%
|
12.37
+136.63%
|
5.23
|
—
|
| Current Assets |
|
6.00
-40.57%
|
10.10
+304.86%
|
2.49
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
4.97
-44.74%
|
9.00
+469.41%
|
1.58
|
—
|
| Cash And Cash Equivalents |
|
4.97
-44.74%
|
9.00
+469.41%
|
1.58
|
—
|
| Cash Financial |
|
4.97
-44.74%
|
9.00
+469.41%
|
1.58
|
—
|
| Receivables |
|
0.12
-40.80%
|
0.20
+255.58%
|
0.06
|
—
|
| Accounts Receivable |
|
0.02
|
0.00
|
—
|
—
|
| Other Receivables |
|
0.06
+374.32%
|
0.01
-76.89%
|
0.06
|
—
|
| Taxes Receivable |
|
0.00
-38.60%
|
0.00
|
—
|
—
|
| Accrued Interest Receivable |
|
0.04
-80.50%
|
0.19
|
—
|
—
|
| Prepaid Assets |
|
0.91
+1.37%
|
0.90
+4.70%
|
0.86
|
—
|
| Total Non Current Assets |
|
4.07
+78.99%
|
2.27
-16.87%
|
2.73
|
—
|
| Net PPE |
|
3.25
+57.55%
|
2.06
-16.57%
|
2.47
|
—
|
| Gross PPE |
|
5.02
+46.38%
|
3.43
-2.78%
|
3.53
|
—
|
| Accumulated Depreciation |
|
-1.77
-29.47%
|
-1.36
-29.63%
|
-1.05
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Land And Improvements |
|
0.59
+57.99%
|
0.37
-5.74%
|
0.39
|
—
|
| Buildings And Improvements |
|
1.99
+87.98%
|
1.06
-3.17%
|
1.10
|
—
|
| Machinery Furniture Equipment |
|
0.45
+35.61%
|
0.33
-1.73%
|
0.34
|
—
|
| Other Properties |
|
1.99
+19.44%
|
1.67
-2.06%
|
1.70
|
—
|
| Goodwill And Other Intangible Assets |
|
0.09
+649.62%
|
0.01
-34.00%
|
0.02
|
—
|
| Goodwill |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
—
|
| Other Intangible Assets |
|
0.09
+668.74%
|
0.01
-34.66%
|
0.02
|
—
|
| Investments And Advances |
|
0.22
+13.27%
|
0.20
-18.52%
|
0.24
|
—
|
| Long Term Equity Investment |
|
0.22
+13.27%
|
0.20
-18.52%
|
0.24
|
—
|
| Non Current Accounts Receivable |
|
0.50
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
1.02
-8.96%
|
1.12
-75.76%
|
4.64
|
—
|
| Current Liabilities |
|
0.61
-15.39%
|
0.72
-82.79%
|
4.17
|
—
|
| Payables And Accrued Expenses |
|
0.44
-15.73%
|
0.52
+26.50%
|
0.41
|
—
|
| Payables |
|
0.08
+1.17%
|
0.08
-57.48%
|
0.18
|
—
|
| Accounts Payable |
|
0.04
+56.93%
|
0.02
+68.29%
|
0.01
|
—
|
| Other Payable |
|
0.04
-26.05%
|
0.05
-68.28%
|
0.16
|
—
|
| Current Accrued Expenses |
|
0.36
-18.57%
|
0.45
+89.32%
|
0.24
|
—
|
| Total Tax Payable |
|
0.00
|
0.00
-100.00%
|
0.00
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.05
+14.07%
|
0.04
-98.92%
|
3.74
|
—
|
| Current Debt |
|
0.04
+10.98%
|
0.03
-99.09%
|
3.74
|
—
|
| Other Current Borrowings |
|
0.04
+10.98%
|
0.03
-99.09%
|
3.74
|
—
|
| Current Capital Lease Obligation |
|
0.01
+30.65%
|
0.01
-17.98%
|
0.01
|
—
|
| Current Deferred Liabilities |
|
0.11
+1199.40%
|
0.01
-7.73%
|
0.01
|
—
|
| Current Deferred Revenue |
|
0.11
+1199.40%
|
0.01
-7.73%
|
0.01
|
—
|
| Other Current Liabilities |
|
0.01
-91.85%
|
0.15
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.42
+2.35%
|
0.41
-14.25%
|
0.48
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.42
+2.35%
|
0.41
-14.25%
|
0.48
|
—
|
| Long Term Debt |
|
0.39
-3.30%
|
0.41
-13.02%
|
0.47
|
—
|
| Long Term Capital Lease Obligation |
|
0.02
|
0.00
-100.00%
|
0.01
|
—
|
| Stockholders Equity |
|
8.97
-20.27%
|
11.25
+1815.76%
|
0.59
|
—
|
| Common Stock Equity |
|
8.97
-20.27%
|
11.25
+1815.76%
|
0.59
|
—
|
| Capital Stock |
|
23.79
+0.31%
|
23.72
+166.13%
|
8.91
|
—
|
| Common Stock |
|
23.79
+0.31%
|
23.72
+166.13%
|
8.91
|
—
|
| Share Issued |
|
11.54
+0.09%
|
11.53
+5.39%
|
10.94
+0.00%
|
10.94
|
| Ordinary Shares Number |
|
11.54
+0.09%
|
11.53
+5.39%
|
10.94
+0.00%
|
10.94
|
| Retained Earnings |
|
-14.85
-20.41%
|
-12.33
-50.41%
|
-8.20
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
+109.30%
|
-0.22
-70.53%
|
-0.13
|
—
|
| Minority Interest |
|
0.08
+8232.74%
|
-0.00
-40.18%
|
-0.00
|
—
|
| Other Equity Adjustments |
|
0.07
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
9.04
-19.57%
|
11.24
+1817.82%
|
0.59
|
—
|
| Total Capitalization |
|
9.36
-19.67%
|
11.65
+1003.69%
|
1.06
|
—
|
| Working Capital |
|
5.39
-42.49%
|
9.38
+661.20%
|
-1.67
|
—
|
| Invested Capital |
|
9.40
-19.58%
|
11.69
+143.89%
|
4.79
|
—
|
| Total Debt |
|
0.46
+3.40%
|
0.45
-89.38%
|
4.22
|
—
|
| Net Debt |
|
—
|
—
|
2.63
+263.19%
|
0.72
|
| Capital Lease Obligations |
|
0.03
+394.78%
|
0.01
-56.14%
|
0.01
|
—
|
| Net Tangible Assets |
|
8.87
-21.01%
|
11.23
+1876.99%
|
0.57
|
—
|
| Tangible Book Value |
|
8.87
-21.01%
|
11.23
+1876.99%
|
0.57
|
—
|
| Available For Sale Securities |
|
—
|
—
|
—
|
—
|
| Duefrom Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Dueto Related Parties Current |
|
—
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Foreign Currency Translation Adjustments |
|
-0.05
+75.27%
|
-0.22
-70.53%
|
-0.13
|
—
|
| Investmentin Financial Assets |
|
0.00
|
—
|
—
|
—
|
| Investmentsin Associatesat Cost |
|
0.22
+13.27%
|
0.20
-18.52%
|
0.24
|
—
|
| Other Equity Interest |
|
—
|
0.07
|
—
|
1.14
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.70
-36.44%
|
-2.71
+23.26%
|
-3.53
-152.52%
|
-1.40
|
| Cash Flow From Continuing Operating Activities |
|
-3.70
-36.44%
|
-2.71
+23.26%
|
-3.53
-152.52%
|
-1.40
|
| Net Income From Continuing Operations |
|
-4.00
-58.47%
|
-2.52
+38.98%
|
-4.13
-32.04%
|
-3.13
|
| Depreciation Amortization Depletion |
|
0.40
+19.75%
|
0.34
-12.01%
|
0.38
-2.98%
|
0.39
|
| Depreciation |
|
0.37
+15.17%
|
0.32
-14.03%
|
0.37
-1.29%
|
0.38
|
| Amortization Cash Flow |
|
0.03
+131.40%
|
0.01
+106.36%
|
0.01
-51.55%
|
0.01
|
| Depreciation And Amortization |
|
0.40
+19.75%
|
0.34
-12.01%
|
0.38
-2.98%
|
0.39
|
| Amortization Of Intangibles |
|
0.03
+131.40%
|
0.01
+106.36%
|
0.01
-51.55%
|
0.01
|
| Other Non Cash Items |
|
-0.10
+65.36%
|
-0.30
-26.84%
|
-0.23
-290.48%
|
0.12
|
| Stock Based Compensation |
|
0.69
|
0.00
|
0.00
|
—
|
| Asset Impairment Charge |
|
0.01
|
0.00
|
0.00
-100.00%
|
0.00
|
| Operating Gains Losses |
|
-0.22
-29.05%
|
-0.17
-166.57%
|
0.25
+2075.11%
|
0.01
|
| Gain Loss On Investment Securities |
|
0.01
+109.49%
|
-0.14
-161.78%
|
0.22
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
|
0.00
-100.00%
|
0.10
-90.94%
|
1.09
|
| Net Foreign Currency Exchange Gain Loss |
|
0.06
+460.54%
|
-0.02
-532.72%
|
-0.00
+88.30%
|
-0.02
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Change In Working Capital |
|
-0.49
-703.74%
|
-0.06
-157.57%
|
0.10
-4.53%
|
0.11
|
| Change In Receivables |
|
-0.56
-604.74%
|
-0.08
-1403.92%
|
-0.01
+96.38%
|
-0.15
|
| Change In Payables And Accrued Expense |
|
-0.00
+99.80%
|
-0.08
-177.25%
|
0.11
-59.17%
|
0.27
|
| Change In Payable |
|
-0.00
+99.80%
|
-0.08
-177.25%
|
0.11
-59.17%
|
0.27
|
| Change In Other Working Capital |
|
0.07
-29.56%
|
0.10
+5140.06%
|
0.00
+119.54%
|
-0.01
|
| Investing Cash Flow |
|
0.93
-17.51%
|
1.13
+141.25%
|
-2.73
-476.97%
|
-0.47
|
| Cash Flow From Continuing Investing Activities |
|
0.93
-17.51%
|
1.13
+141.25%
|
-2.73
-476.97%
|
-0.47
|
| Net PPE Purchase And Sale |
|
-0.64
+54.45%
|
-1.40
-2301.96%
|
-0.06
+87.68%
|
-0.47
|
| Purchase Of PPE |
|
-0.64
+54.45%
|
-1.40
-2301.96%
|
-0.06
+87.70%
|
-0.47
|
| Sale Of PPE |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
-0.70
+52.95%
|
-1.49
-2463.57%
|
-0.06
+87.70%
|
-0.47
|
| Net Investment Purchase And Sale |
|
0.27
-89.06%
|
2.50
+190.14%
|
-2.77
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
-2.77
|
0.00
|
| Sale Of Investment |
|
0.27
-89.06%
|
2.50
|
—
|
—
|
| Net Business Purchase And Sale |
|
1.22
+671.26%
|
0.16
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Gain Loss On Sale Of Business |
|
-0.29
|
0.00
|
0.00
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.07
+30.70%
|
-0.09
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
-0.07
+30.70%
|
-0.09
|
0.00
|
0.00
|
| Net Other Investing Changes |
|
-0.02
+95.90%
|
-0.50
|
—
|
—
|
| Financing Cash Flow |
|
0.21
+421.53%
|
-0.06
-100.59%
|
10.92
+1027.25%
|
0.97
|
| Cash Flow From Continuing Financing Activities |
|
0.21
+421.53%
|
-0.06
-100.59%
|
10.92
+1027.25%
|
0.97
|
| Net Issuance Payments Of Debt |
|
-0.05
-20.10%
|
-0.04
+86.90%
|
-0.34
-164.39%
|
-0.13
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
0.30
|
| Repayment Of Debt |
|
-0.05
-20.10%
|
-0.04
+86.90%
|
-0.34
+20.60%
|
-0.43
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
0.30
|
| Long Term Debt Payments |
|
-0.05
-20.10%
|
-0.04
+86.90%
|
-0.34
+20.60%
|
-0.43
|
| Net Long Term Debt Issuance |
|
-0.05
-20.10%
|
-0.04
+86.90%
|
-0.34
-164.39%
|
-0.13
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.30
|
| Short Term Debt Payments |
|
—
|
—
|
-0.30
+14.29%
|
-0.35
|
| Net Short Term Debt Issuance |
|
—
|
—
|
-0.30
-500.00%
|
-0.05
|
| Net Common Stock Issuance |
|
0.28
|
0.00
-100.00%
|
11.31
+824.80%
|
1.22
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-2.56
-55.29%
|
-1.65
-135.39%
|
4.66
+615.82%
|
-0.90
|
| Effect Of Exchange Rate Changes |
|
-0.04
-134.69%
|
0.12
+1003.29%
|
-0.01
+55.37%
|
-0.03
|
| Beginning Cash Position |
|
4.70
-24.54%
|
6.22
+294.01%
|
1.58
-37.13%
|
2.51
|
| End Cash Position |
|
2.10
-55.39%
|
4.70
-24.54%
|
6.22
+294.01%
|
1.58
|
| Free Cash Flow |
|
-4.40
-4.67%
|
-4.20
-17.13%
|
-3.59
-91.73%
|
-1.87
|
| Common Stock Issuance |
|
0.28
|
0.00
-100.00%
|
11.31
+824.80%
|
1.22
|
| Earnings Losses From Equity Investments |
|
0.01
+146.43%
|
-0.01
-144.12%
|
0.03
-7.00%
|
0.03
|
| Interest Paid CFF |
|
-0.02
-2.92%
|
-0.02
+56.52%
|
-0.05
+62.68%
|
-0.13
|
| Interest Received CFI |
|
0.16
-65.16%
|
0.47
+373.30%
|
0.10
|
0.00
|
| Interest Received CFO |
|
0.00
-100.00%
|
0.00
+288.76%
|
0.00
-70.29%
|
0.00
|
| Issuance Of Capital Stock |
|
0.28
|
0.00
-100.00%
|
11.31
+824.80%
|
1.22
|
| Sale Of Business |
|
1.22
+671.26%
|
0.16
|
0.00
|
—
|
| Taxes Refund Paid |
|
0.00
|
0.00
+100.00%
|
-0.00
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|